Astellas Pharma

Update in progress

4503.T (Tokyo)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - General

Astellas Pharma Inc. is a global pharmaceutical company that develops, markets, imports and exports medicines in Japan and worldwide. It offers XTANDI (prostate cancer), XOSPATA (AML), VYLOY (gastric cancer), PADCEV (metastatic urothelial cancer), VEOZAH (vasomotor symptoms), IZERVAY (geographic atrophy), EVRENZO (anemia in CKD), Betanis/Myrabetriq/BETMIGA (overactive bladder), and Prograf immunosuppressant. It partners with xFOREST Therapeutics and Roche Diabetes Care Japan. Founded 1923, headquartered in Chuo, Japan.

Company score

Sentiment: 1.85; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.75; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 2.17; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.52; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 1.01; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 1.43; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive